Zachary A Cooper
Zachary A Cooper
Verified email at - Homepage
Cited by
Cited by
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ...
Science 359 (6371), 97-103, 2018
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ...
Nature 487 (7408), 500-504, 2012
Loss of PTEN promotes resistance to T cell–mediated immunotherapy
W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ...
Cancer discovery 6 (2), 202-216, 2016
Defining T cell states associated with response to checkpoint immunotherapy in melanoma
M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ...
Cell 175 (4), 998-1013. e20, 2018
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ...
Science 357 (6356), 1156-1160, 2017
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
D Nejman, I Livyatan, G Fuks, N Gavert, Y Zwang, LT Geller, ...
Science 368 (6494), 973-980, 2020
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
DT Frederick, A Piris, AP Cogdill, ZA Cooper, C Lezcano, CR Ferrone, ...
Clinical cancer research 19 (5), 1225-1231, 2013
Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade
PL Chen, W Roh, A Reuben, ZA Cooper, CN Spencer, PA Prieto, JP Miller, ...
Cancer discovery 6 (8), 827-837, 2016
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
W Roh, PL Chen, A Reuben, CN Spencer, PA Prieto, JP Miller, ...
Science translational medicine 9 (379), eaah3560, 2017
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors
DJ Konieczkowski, CM Johannessen, O Abudayyeh, JW Kim, ZA Cooper, ...
Cancer discovery 4 (7), 816-827, 2014
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
N Wagle, EM Van Allen, DJ Treacy, DT Frederick, ZA Cooper, ...
Cancer discovery 4 (1), 61-68, 2014
The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies
L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ...
Nature genetics 47 (3), 250-256, 2015
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice
C Liu, W Peng, C Xu, Y Lou, M Zhang, JA Wargo, JQ Chen, HS Li, ...
Clinical cancer research 19 (2), 393-403, 2013
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
A Kaur, MR Webster, K Marchbank, R Behera, A Ndoye, CH Kugel, ...
Nature 532 (7598), 250-254, 2016
Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma
JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington, S Wardell, C Liu, ...
Clinical Cancer Research 18 (19), 5329-5340, 2012
Elucidating Distinct Roles for NF1 in Melanomagenesis
O Maertens, B Johnson, P Hollstein, DT Frederick, ZA Cooper, ...
Cancer discovery 3 (3), 338-349, 2013
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised …
RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ...
The Lancet Oncology 19 (2), 181-193, 2018
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade
ZA Cooper, VR Juneja, PT Sage, DT Frederick, A Piris, D Mitra, JA Lo, ...
Cancer immunology research 2 (7), 643-654, 2014
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2
MP O'Connell, K Marchbank, MR Webster, AA Valiga, A Kaur, A Vultur, ...
Cancer discovery 3 (12), 1378-1393, 2013
Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy
MP Smith, H Brunton, EJ Rowling, J Ferguson, I Arozarena, Z Miskolczi, ...
Cancer cell 29 (3), 270-284, 2016
The system can't perform the operation now. Try again later.
Articles 1–20